Multinational healthcare company Grifols announced a temporary nationwide pause on all plasma collection across Canada, effective Friday. The decision follows a series of non-compliance ratings issued by Health Canada regarding equipment maintenance, staff qualifications, and donor screening protocols at multiple facilities.
The Bottom Line
- Operational Halt: Grifols is suspending collection at all Canadian donation sites, citing what the company termed “unfounded attention” following public scrutiny and regulatory actions.
- Regulatory Action: Health Canada issued a notice of non-compliance for a Winnipeg site on Taylor Avenue, marking the sixth such rating for Grifols facilities across New Brunswick, Ontario, Manitoba, Saskatchewan, and Alberta since 2022.
- Supply Chain Assurance: Federal health officials confirmed that the temporary closure will have no impact on the safety and security of Canada’s national blood supply.
Regulatory Deficiencies and Inspection History
The operational shutdown comes on the same day Health Canada published the findings of a compliance investigation. According to federal inspection summaries, the Grifols site located on Taylor Avenue in Winnipeg failed to execute sufficient corrective and preventive actions when required. Inspectors also noted that equipment calibration, cleaning, maintenance records, and staff competency evaluations “were not always sufficient.”
Data released by Health Canada under access to information laws indicate that a total of 25 serious adverse reactions have been documented at Grifols-operated centers since 2018. Publicly listed inspection records show that licensed blood establishments run by the multinational firm have received non-compliant ratings spanning five provinces: New Brunswick, Ontario, Manitoba, Saskatchewan, and Alberta. An active inspection remains ongoing at a facility located in Etobicoke, Ontario.
Public Advocacy and Safety Debates
The suspension follows sustained pressure from provincial advocacy groups, including the Manitoba Health Coalition. Noah Schulz, provincial director of the coalition, stated, “We see this pattern of poor practices.” Advocacy groups have repeatedly urged federal regulators to ban paid plasma donations altogether, arguing that being for-profit means the company is encouraged to run things “as cheaply” as possible.
Public scrutiny intensified following the deaths of two individuals who donated plasma at Winnipeg clinics. Among them was 22-year-old international student Rodiyat Alabede, who passed away on October 25. Katherine Lanteigne, an advocate representing Alabede’s family, stated that “donors in Canada are safe” now that the facilities are shuttered, while continuing to call for an immediate suspension of the company’s operating licenses. Conversely, Health Canada officials maintained that investigators found no link between the two fatalities and the plasma donation process.
Market Context and Compliance Metrics
Operating in a tightly regulated biologics market requires stringent adherence to federal standards to protect donor health and product integrity. Below is an overview of the regulatory findings and operational metrics associated with the recent Health Canada actions against the multinational plasma operator.
| Metric / Parameter | Regulatory Finding / Status |
|---|---|
| Total Non-Compliance Ratings (Since 2022) | 6 notices issued across New Brunswick, Ontario, Manitoba, Saskatchewan, and Alberta |
| Reported Adverse Reactions (Since 2018) | 25 serious adverse reactions documented across active Grifols centers |
| Effective Date of Nationwide Pause | Friday |
| Impact on National Blood Supply | Confirmed no impact by Health Canada officials |
In a formal statement released Thursday, Grifols defended its operating history, asserting that donor safety and the safety of plasma collection “has never been compromised.” The company confirmed it had informed Health Canada of the voluntary shutdown on Wednesday and expressed readiness to engage in transparent discussions. A spokesperson for Health Minister Marjorie Michel confirmed that the federal agency will collaborate closely with Grifols to ensure all identified deficiencies are fully resolved before any collection sites are permitted to resume operations.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
